A growth-stage investor and former operator focused on scaling SaaS and consumer-facing tech companies, with experience in commercial strategy, fundraising and M&A execution. Her profile includes operator roles at startups and venture investments across B2B software, marketplaces and digital consumer brands; Ashley Meredith is frequently engaged as board observer or independent director supporting KPI-driven growth and go-to-market optimization. She is positioned for roles that bridge operator instincts and investment discipline, prioritizing unit economics, retention metrics and capital-efficient expansion.
A growth-stage investor and former operator focused on scaling SaaS and consumer-facing tech companies, with experience in commercial strategy, fundraising and M&A execution. Her profile includes operator roles at startups and venture investments across B2B software, marketplaces and digital consumer brands; Ashley Meredith is frequently engaged as board observer or independent director supporting KPI-driven growth and go-to-market optimization. She is positioned for roles that bridge operator instincts and investment discipline, prioritizing unit economics, retention metrics and capital-efficient expansion.
Focuses on growth-stage SaaS, marketplaces and consumer tech where operator experience accelerates commercial scale. Emphasizes KPI-driven underwriting—unit economics, retention, LTV/CAC and margin expansion—favoring capital-efficient paths to repeatable revenue. Deploys staged capital with follow-on reserves, active board-level engagement and go-to-market playbooks to de-risk commercialization. Time horizon targets durable scale rather than quick exits; risk discipline centers on measurable traction, customer economics and founder alignment, with preference for repeatable GTM and strong unit-level margins.
Focuses on growth-stage SaaS, marketplaces and consumer tech where operator experience accelerates commercial scale. Emphasizes KPI-driven underwriting—unit economics, retention, LTV/CAC and margin expansion—favoring capital-efficient paths to repeatable revenue. Deploys staged capital with follow-on reserves, active board-level engagement and go-to-market playbooks to de-risk commercialization. Time horizon targets durable scale rather than quick exits; risk discipline centers on measurable traction, customer economics and founder alignment, with preference for repeatable GTM and strong unit-level margins.
| Trades 3722 | Longs Won 2252/3722 60% | Profit Factor 4.91 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $262,185.2 |
| Average Win $61,369.66 | Best Trade (Aug 14) $13.47M | Sharpe Ratio -10.11 |
| Average Loss -$19,159.57 | Worst Trade (Aug 02) -$619,555.11 | Z-Score 12.41 (100%) |
| Commissions $0 | Avg. Trade Length 8m 3w | Expectancy $29,453.11 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 29,412 | 26,471 | 23,529 | 20,588 | 17,647 | 14,706 | 11,765 | 8,824 | 5,882 | 2,941 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAOI Applied Optoelectronics, Inc. | 3,807 | $322,034.2 | $359,076.24 | - | $37,042.04 | 11.5% | +4.672% |
AAON Aaon Inc. | 1,864 | $236,467 | $166,007.84 | - | -$70,459.16 | -29.8% | +1.678% |
AAPL Apple Inc. | 38,715 | $9.21M | $11.96M | - | $2.75M | 29.81% | -7.354% |
AARD Aardvark Therapeutics, Inc. | 10,066 | $38,653.44 | $66,435.6 | - | $27,782.16 | 71.87% | +3.125% |
ABBV AbbVie Inc. | 7,378 | $1.59M | $1.85M | - | $257,764.66 | 16.17% | -2.513% |
ABG Asbury Automotive Group Inc. | 1,488 | $333,889.68 | $344,769.6 | - | $10,879.92 | 3.26% | -0.618% |
ABNB Airbnb, Inc. | 2,992 | $396,152.7 | $453,347.84 | - | $57,195.14 | 14.44% | -0.368% |
ABR Arbor Realty Trust Inc. | 17,277 | $93,641 | $86,557.77 | - | -$7,083.23 | -7.56% | +4.593% |
ABT Abbott Laboratories | 5,597 | $507,906 | $591,602.9 | - | $83,696.9 | 16.48% | +0.085% |
ABUS Arbutus Biopharma Corporation | 18,300 | $88,023.01 | $79,422 | - | -$8,601.01 | -9.77% | -1.587% |
ACA Arcosa Inc. | 2,253 | $244,371.11 | $327,135.6 | - | $82,764.49 | 33.87% | -0.021% |
ACAD Acadia Pharmaceuticals Inc. | 12,694 | $320,446.9 | $328,393.78 | - | $7,946.88 | 2.48% | -2.561% |
ACH Accendra Health, Inc. | 20,113 | $46,542.41 | $62,149.17 | - | $15,606.76 | 33.53% | -7.485% |
ACI Albertsons Companies, Inc. | 16,200 | $219,186 | $187,596 | - | -$31,590 | -14.41% | -0.172% |
ACIW ACI Worldwide, Inc. | 11,546 | $475,501.64 | $661,932.18 | - | $186,430.54 | 39.21% | -0.624% |
ACLS Axcelis Technologies, Inc. | 2,622 | $211,197.17 | $341,856.36 | - | $130,659.19 | 61.87% | +4.129% |
ACMR Acm Research Inc. | 2,956 | $375,087 | $231,957.32 | - | -$143,129.68 | -38.16% | -0.229% |
ACN Accenture plc Class A | 1,628 | $407,981.7 | $270,117.76 | - | -$137,863.94 | -33.79% | +1.611% |
ACRE Ares Commercial Real Estate Corporation | 52,842 | $251,948.47 | $225,106.92 | - | -$26,841.55 | -10.65% | -1.16% |
ACTG Acacia Research Corporation | 14,416 | $54,776.59 | $63,862.88 | - | $9,086.29 | 16.59% | +0.454% |